Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Recombine Endostatin in Alliance With Neoadjuvant Chemotherapy Followed by Concurrent Chemoradiation in Locoregionally Advanced Nasopharyngeal Carcinoma

NCT01689558 is registered in ClinicalTrials.gov with Jin Feng as lead sponsor.

NCT NCT01689558
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01689558 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Recombine Endostatin in Alliance With Neoadjuvant Chemotherapy Followed by Concurrent Chemoradiation in Locoregionally Advanced Nasopharyngeal Carcinoma
Lead sponsor
Jin Feng
Phase
Phase 2/3
Overall status
Unknown status
Start date
December 31, 2011
Completion date
January 31, 2017
Enrollment
60 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

1、enough cases, 2、elekta precise 1343 digital control electron linear accelerator, can undertake nasopharyngeal carcinoma specimens in the materia，, image department of nose pharynx ministry mri dynamic testing,